HomeCompareGRTS vs SBUX

GRTS vs SBUX: Dividend Comparison 2026

GRTS yields 6211.18% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GRTS wins by $514736922231177.75M in total portfolio value
10 years
GRTS
GRTS
● Live price
6211.18%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$514736922231177.94M
Annual income
$498,935,081,000,370,800,000.00
Full GRTS calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — GRTS vs SBUX

📍 GRTS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGRTSSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GRTS + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GRTS pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GRTS
Annual income on $10K today (after 15% tax)
$527,950.31/yr
After 10yr DRIP, annual income (after tax)
$424,094,818,850,315,200,000.00/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, GRTS beats the other by $424,094,818,850,315,100,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GRTS + SBUX for your $10,000?

GRTS: 50%SBUX: 50%
100% SBUX50/50100% GRTS
Portfolio after 10yr
$257368461115589.06M
Annual income
$249,467,540,500,185,450,000.00/yr
Blended yield
96.93%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

GRTS
Analyst Ratings
7
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$4.67
+14403.1% upside vs current
Range: $3.00 — $6.00
Altman Z
-9.7
Piotroski
1/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GRTS buys
0
SBUX buys
0
No recent congressional trades found for GRTS or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGRTSSBUX
Forward yield6211.18%2.84%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$514736922231177.94M$167.0K
Annual income after 10y$498,935,081,000,370,800,000.00$71,136.45
Total dividends collected$513674666624982.00M$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyBuy
Analyst price target$4.67$104.00

Year-by-year: GRTS vs SBUX ($10,000, DRIP)

YearGRTS PortfolioGRTS Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$631,818$621,118.01$11,121$420.68+$620.7KGRTS
2$37,352,078$36,676,032.53$12,548$648.40+$37.34MGRTS
3$2,066,348,794$2,026,382,070.58$14,440$1,013.98+$2066.33MGRTS
4$106,978,454,906$104,767,461,696.78$17,068$1,617.30+$106978.44MGRTS
5$5,183,619,185,269$5,069,152,238,519.27$20,912$2,649.52+$5183619.16MGRTS
6$235,102,301,025,325$229,555,828,497,087.03$26,875$4,499.29+$235102301.00MGRTS
7$9,981,906,672,630,884$9,730,347,210,533,788.00$36,771$8,014.12+$9981906672.59MGRTS
8$396,781,870,195,426,800$386,101,230,055,711,700.00$54,542$15,197.11+$396781870195.37MGRTS
9$14,768,075,916,642,124,000$14,343,519,315,533,017,000.00$89,602$31,242.49+$14768075916642.03MGRTS
10$514,736,922,231,177,940,000$498,935,081,000,370,800,000.00$167,011$71,136.45+$514736922231177.75MGRTS

GRTS vs SBUX: Complete Analysis 2026

GRTSStock

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors comprising metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. It has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Full GRTS Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this GRTS vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GRTS vs SCHDGRTS vs JEPIGRTS vs OGRTS vs KOGRTS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.